Cite
Zhang L, Coombes J, Pascoe EM, et al. The effect of pentoxifylline on oxidative stress in chronic kidney disease patients with erythropoiesis-stimulating agent hyporesponsiveness: Sub-study of the HERO trial. Redox Rep. 2016;21(1):14-23doi: 10.1179/1351000215Y.0000000022.
Zhang, L., Coombes, J., Pascoe, E. M., Badve, S. V., Dalziel, K., Cass, A., Clarke, P., Ferrari, P., McDonald, S. P., Morrish, A. T., Pedagogos, E., Perkovic, V., Reidlinger, D., Scaria, A., Walker, R., Vergara, L. A., Hawley, C. M., Johnson, D. W., & On Behalf Of The Hero Study Collaborative Group. (2016). The effect of pentoxifylline on oxidative stress in chronic kidney disease patients with erythropoiesis-stimulating agent hyporesponsiveness: Sub-study of the HERO trial. Redox report : communications in free radical research, 21(1), 14-23. https://doi.org/10.1179/1351000215Y.0000000022
Zhang, Lei, et al. "The effect of pentoxifylline on oxidative stress in chronic kidney disease patients with erythropoiesis-stimulating agent hyporesponsiveness: Sub-study of the HERO trial." Redox report : communications in free radical research vol. 21,1 (2016): 14-23. doi: https://doi.org/10.1179/1351000215Y.0000000022
Zhang L, Coombes J, Pascoe EM, Badve SV, Dalziel K, Cass A, Clarke P, Ferrari P, McDonald SP, Morrish AT, Pedagogos E, Perkovic V, Reidlinger D, Scaria A, Walker R, Vergara LA, Hawley CM, Johnson DW, On Behalf Of The Hero Study Collaborative Group. The effect of pentoxifylline on oxidative stress in chronic kidney disease patients with erythropoiesis-stimulating agent hyporesponsiveness: Sub-study of the HERO trial. Redox Rep. 2016 Jan;21(1):14-23. doi: 10.1179/1351000215Y.0000000022. Epub 2016 Mar 04. PMID: 26083328; PMCID: PMC6837737.
Copy
Download .nbib